Pulmonary Artery Pressure–Flow Relations after Prostacyclin in Primary Pulmonary Hypertension
- 1 February 2002
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 165 (3) , 338-340
- https://doi.org/10.1164/ajrccm.165.3.2106033
Abstract
Exercise tolerance improves within a few weeks after prostacyclin initiation in patients with primary pulmonary hypertension even in the absence of significant changes in resting pulmonary vascular resistance and/or in patients who fail to respond to an acute vasodilator challenge. We tested the hypothesis that this early effect of prostacyclin may be ascribable to an improved pressure-flow response of the pulmonary circulation to exercise. Pulmonary hemodynamic variables at rest and during exercise and the 6-min walking distance were determined before and after 6 wk of continuous intravenous prostacyclin treatment (11 +/- 1.5 ng/kg/min) in seven patients unresponsive to an acute nitric oxide vasodilator test. Mean pulmonary arterial pressure/cardiac index coordinates obtained during exercise were pooled, and the slopes of these plots were compared using covariance analysis. All hemodynamic variables at rest were unchanged after prostacyclin. By contrast, the 6-min walking distance improved in all patients (mean increase, 81 m) and the slope of the mean pulmonary artery pressures/cardiac indexes plot decreased with prostacyclin, from 18.2 to 13.1 mm Hg/L/min/m(2) (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise.Keywords
This publication has 18 references indexed in Scilit:
- Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot studyEuropean Respiratory Journal, 1999
- Partitioning of Pulmonary Vascular Resistance in Primary Pulmonary Hypertension 11This study was supported by Grant 3.4517.95 from the Fonds de la Recherche Scientifique Médicale Belgium and by the Belgian Foundation for Cardiac Surgery, Brussels. Sophia Abdel Kafi was a fellow of the Erasmus Foundation, Brussels.Journal of the American College of Cardiology, 1998
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Medical management of primary pulmonary hypertensionEuropean Respiratory Journal, 1996
- Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary HypertensionCirculation, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Role of pharmacologic tests in the treatment of primary pulmonary hypertensionThe American Journal of Cardiology, 1995
- Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.Heart, 1993
- The pressure-flow response of the pulmonary circulation in patients with heart failure and pulmonary vascular disease.Circulation, 1985
- On pulmonary vascular resistance: The need for more precise definitionThe American Journal of Cardiology, 1985